新发传染病电子杂志2026，Vol.11Issue(2)：51-55,5.DOI:10.19871/j.cnki.xfcrbzz.2026.02.010
利奈唑胺治疗耐多药结核病患者发生神经病变的危险因素分析
Risk factors for neuropathy in multidrug-resistant tuberculosis patients treated with linezolid
摘要
Abstract
Objective To investigate the risk factors for neuropathy in patients with multidrug-resistant tuberculosis(MDR-TB)treated with linezolid(LZD),so as to provide a basis for early clinical identification of high-risk populations,optimized medication monitoring and reduction of the risk of neuropathy.Method This study enrolled MDR-TB patients treated with linezolid(600 mg once daily for 6-9 months)at Shenzhen Third People's Hospital from May 31,2019,to December 19,2021 as part of the SEAL-MDR trial(safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis:a multicenter randomized withdrawal trial and a single-arm trial).Participants were categorized into groups based on the occurrence of peripheral neuropathy or optic neuropathy.Binary logistic regression analysis was used to identify potential risk factors for neuropathy among these patients treated with LZD.Result A total of 120 patients were enrolled in this study,among which 90 patients(75.00%)developed peripheral neuropathy,while 30(25.00%)did not.Similarly,86(71.67%)developed optic neuropathy,while 30(25.00%)did not.Female sex(OR=3.774,95%CI:1.178-12.090,P=0.025)and age(OR=1.034,95%CI:1.001-1.068,P=0.045)were risk factors for peripheral neuropathy in MDR-TB patients treated with LZD.Non-local patient status(OR=2.629,95%CI:1.050-6.586,P=0.039)was a risk factor for optic neuropathy in these patients.Conclusion MDR-TB patients treated with LZD throughout the course of therapy have a higher risk of developing neuropathy.Clinical attention should be focused on elderly patients,females,and non-local patients,with enhanced monitoring and intervention measures.关键词
利奈唑胺/耐多药结核病/神经病变/周围神经炎/视神经炎/危险因素Key words
Linezolid/multidrug-resistant tuberculosis/Neuropathy/Peripheral neuropathy/Optic neuropathy/Risk factors分类
医药卫生引用本文复制引用
郑健,胡秋萌,王豪朋,张培泽,邓国防..利奈唑胺治疗耐多药结核病患者发生神经病变的危险因素分析[J].新发传染病电子杂志,2026,11(2):51-55,5.基金项目
1.广州国家实验室项目(GZNL2024A01030) （GZNL2024A01030）
2.深圳医学研究项目(C202401026) （C202401026）
3.深圳市第三人民医院院级课题项目(2022098) （2022098）
